RIM
AIMT

RS Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

RS Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$5.82M Sell
538,230
-293,710
-35% -$3.99M 0.06% 259
2016
Q1 		$11.3M Buy
831,940
+27,797
+3% +$434K 0.11% 233
2015
Q4 		$14.8M Buy
804,143
+88,180
+12% +$1.63M 0.13% 210
2015
Q3 		$18.1M Buy
+715,963
New +$16.7M 0.16% 191

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RS Investment Management's AIMT Position: Q2 2016 in Review

RS Investment Management reduced its Aimmune Therapeutics (AIMT) stake by 35% in Q2 2016, selling an estimated $3.99M and leaving 538,230 shares worth $5.82M. The position accounts for 0.06% of the portfolio, ranked #259.

RS Investment Management first reported a position in AIMT in Q3 2015 and has held it in 4 quarters since. The position peaked at $18.1M in Q3 2015. 74 funds tracked by Wall St. Rank hold AIMT as of Q2 2016.

  • RS Investment Management held 538,230 shares of Aimmune Therapeutics worth $5.82M as of Q2 2016.
  • RS Investment Management sold 293,710 Aimmune Therapeutics shares in Q2 2016, an estimated $3.99M.
  • Aimmune Therapeutics made up 0.06% of RS Investment Management's portfolio in Q2 2016, its #259 holding.
  • RS Investment Management first reported a position in Aimmune Therapeutics in Q3 2015 and has held it in 4 quarters since.
  • RS Investment Management's Aimmune Therapeutics position peaked at $18.1M in Q3 2015.
  • 74 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.